Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) CAO Sells 1,413 Shares of Company Stock

Key Points

• Jazz Pharmaceuticals CAO Patricia Carr sold 1,413 shares at an average price of $231.36, totaling about $326,912. She retained 6,512 shares after reducing her position by 17.83%.
• Jazz reported quarterly revenue of $1.24 billion, up 10.4% year over year, beating analysts’ expectations of $1.21 billion. Earnings per share also topped estimates, coming in at a loss of $3.88 versus the expected loss of $4.03.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $293.45. Shares traded at $234.76 in Friday’s session.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) CAO Patricia Carr sold 1,413 shares of the business's stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $231.36, for a total transaction of $326,911.68. Following the transaction, the chief accounting officer directly owned 6,512 shares of the company's stock, valued at approximately $1,506,616.32. This trade represents a 17.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock traded up $7.44 during trading on Friday, hitting $234.76. 887,560 shares of the stock were exchanged, compared to its average volume of 933,246. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.58 and a current ratio of 1.82. The stock's fifty day moving average is $229.71 and its 200 day moving average is $217.40. The stock has a market cap of $15.07 billion, a PE ratio of 79.85, a P/E/G ratio of 0.47 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 12 month low of $128.80 and a 12 month high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, topping the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The firm had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.21 billion. During the same quarter in the prior year, the firm earned $8.13 EPS. Jazz Pharmaceuticals's quarterly revenue was up 10.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 10.84 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of JAZZ. Castleark Management LLC acquired a new position in shares of Jazz Pharmaceuticals during the 1st quarter worth $9,214,000. SEB Asset Management AB acquired a new stake in shares of Jazz Pharmaceuticals in the 1st quarter valued at $8,765,000. Bank of America Corp DE boosted its holdings in Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company's stock worth $191,848,000 after purchasing an additional 99,656 shares in the last quarter. California Public Employees Retirement System boosted its holdings in Jazz Pharmaceuticals by 10.6% in the first quarter. California Public Employees Retirement System now owns 124,583 shares of the specialty pharmaceutical company's stock worth $23,552,000 after purchasing an additional 11,915 shares in the last quarter. Finally, Angeles Wealth Management LLC acquired a new position in Jazz Pharmaceuticals during the second quarter worth $1,221,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently commented on JAZZ. UBS Group raised their target price on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a "buy" rating in a research report on Friday, September 11th. Wells Fargo & Company boosted their price target on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 4th. Barclays increased their price target on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the stock an "overweight" rating in a research note on Tuesday. Morgan Stanley raised their price target on Jazz Pharmaceuticals from $314.00 to $319.00 and gave the company an "overweight" rating in a report on Tuesday. Finally, Wall Street Zen cut shares of Jazz Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $293.45.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz's sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.